The effects of obstacle size and timing on prefrontal cortex activation in patients with Parkinson’s disease
Objective: To evaluate the effects of obstacle height and anticipation time on prefrontal cortex (PFC) activation in patients with Parkinson's disease (PD) and older adults.…Memantine and 3D gait analysis in patient with Parkinson’s disease: an observer-blind randomized clinical trial
Objective: To examine the efficacy of memantine (20 mg), a non-competitive NMDAR antagonist, in the treatment of gait impairment in PD patients with mild cognitive…Ambulatory monitoring of electrodermal activity (EDA) and Heart Rate Variability (HRV) for prediction of motor fluctuations in Parkinson’s Disease (PD)
Objective: To determine whether changes in EDA and HRV are associated with motor fluctuations in patients with PD Background: EDA and HRV are affected in…High cost of medications for Parkinson’s Disease patients in a rural population of Gujarat, India
Objective: To understand the economic burden of the cost of Parkinson’s Disease (PD) medications for outpatients receiving care at Shree Krishna Hospital (SKH) in Karamsad,…Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist
Objective: To evaluate whether an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A receptor antagonist preladenant prevent the onset of…The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson’s disease
Objective: To examine the contributions of systemic factors to clinically relevant cognitive decline in Parkinson’s disease (PD), we studied the impact of cardiometabolic and inflammatory…Amylin and insulin in Parkinson’s disease patients: a clinical and metabolic study
Objective: To assess the possible connection between PD and glucose metabolism (GM) by analyzing the levels of biomarkers of GM in patients with PD. Background:…THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)
Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuatedPrecision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid…Body Mass Gain in Parkinson’s Disease Following Deep Brain Stimulation: A Systematic Review
Objective: To investigate the extent and time course of body mass gain after subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson’s disease (PD) patients.…Does Anticholinergic Burden Affect the Outcomes in Patients Diagnosed with Parkinson’s Disease?
Objective: To explore the impact of an anticholinergic burden on various outcomes in Parkinson’s disease. Background: Over 600 different medications possess some anticholinergic effect.[1] There…
- « Previous Page
- 1
- …
- 127
- 128
- 129
- 130
- 131
- …
- 217
- Next Page »